Table 2.
LM Leiomyoma, LMS Leiomyosarcoma, LMS—Rec Recurrent leiomyosarcoma, LMS—Met Metastatic leiomyosarcoma, ESS Endometrial stromal sarcoma, STUMP Smooth muscle tumor of uncertain malignant potential, SRC Sarcoma, Med Median, PD-L1 Programmed death-ligand 1, PD-1 Programmed cell death protein 1, CTLA-4 Cytotoxic T-lymphocyte-associated protein 4, IDO Indoleamine 2,3-dioxygenase, n + Number of positive cases, + Positive; Combined n + , at least one of the immune checkpoints is positive; Red, significant difference (p-value ≤ 0.05); Blue, borderline significant difference (0.05 < p-value < 0.1).